Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | RHEB | Q15382 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3761717 | 0.81 | MAPT (0.44) | IMPDH2MAPTMEN1KMT2AMDM2 | |
| SCHEMBL3220763 | 0.77 | IMPDH2 (0.42) | IMPDH2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL27983399 | 0.77 | IMPDH2 (0.42) | IMPDH2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL20656048 | 0.77 | NR3C1 (0.47) | IMPDH2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL27844923 | 0.75 | MAPT (0.44) | IMPDH2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL30344324 | 0.74 | IMPDH2 (1.00) | IMPDH2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1778037 | 0.74 | IMPDH2 (1.00) | IMPDH2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL14819171 | 0.74 | IMPDH2 (0.43) | IMPDH2KDM4EPRKCQPRKCDSMN1; SMN2 | |
| SCHEMBL4329685 | 0.74 | HTR2C (0.62) | IMPDH2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL2262349 | 0.73 | ASH1L (0.41) | IMPDH2MAPTMEN1KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113564623-A | Method for preparing isatin compound by electrochemically oxidizing N-substituted indole derivative | 福建师范大学 | 2021-10-29 | — | — | CN | claimed |
| EP-4380943-A1 | METHOD FOR THE SILYLATION OF A C-H BOND WITH A SILYLATED DIAZENE | SORBONNE UNIVERSITE (FR) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023012494-A1 | METHOD FOR THE SILYLATION OF A C-H BOND WITH A SILYLATED DIAZENE | SORBONNE UNIVERSITE (FR) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023012494-A1 | METHOD FOR THE SILYLATION OF A C-H BOND WITH A SILYLATED DIAZENE | SORBONNE UNIVERSITE (FR) | 2023-02-09 | — | — | WO | disclosed |
| CN-113564623-A | Method for preparing isatin compound by electrochemically oxidizing N-substituted indole derivative | 福建师范大学 | 2021-10-29 | — | — | CN | disclosed |
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-9868722-B2 | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| CN-106458996-A | Fused pyrimidines as inhibitors of the p97 complex | 克里弗生物科学公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. | 2005-06-30 | — | — | US | disclosed |
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082625-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | IMPDH2 3914/4885MAPT 2762/4885MEN1 668/4885 |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | PTH1R, PTMS, SOST | IMPDH2 2755/4885MAPT 1739/4885MEN1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.